Patent ID: 8481039

Claim:
A method for treating a cancer in a subject, wherein the cancer cells exhibit cell membrane-bound HB-EGF or membrane type HB-EGF at the cell surface, said method comprising administering to the subject a therapeutically effective amount of a monoclonal antibody that binds to cell membrane-bound HB-EGF or membrane type HB-EGF, wherein said monoclonal antibody comprises a heavy chain variable region and a light chain variable region comprising complementarity determining regions (CDRs) comprising the amino acid sequence of the corresponding CDRs of the heavy chain variable region and light chain variable region of a monoclonal antibody produced by a hybridoma selected from KM3579 (deposited under accession number FERM BP-10491), KM3567 (deposited under accession number FERM BP-10573) and KM3566 (deposited under accession number FERM BP-10490), wherein said monoclonal antibody is capable of mediating antibody-dependent cellular cytotoxicity (ADCC) directed against the cancer cells, thereby treating the cancer in the subject.